Minoryx Therapeutics develops leriglitazone, an oral, brain‑penetrant selective PPAR‑γ agonist, to treat X‑linked adrenoleukodystrophy and other orphan central nervous system disorders by restoring mitochondrial function and reducing neuroinflammation. Clinical data from the phase 2/3 ADVANCE trial and pediatric NEXUS study demonstrate slowed cerebral lesion progression and disease stabilization, supporting ongoing phase 3 CALYX and additional neurodegenerative programs.
Funding
$31.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CFFounders
Product
Problem
Patients with rare, orphan central nervous system (CNS) disorders such as X‑linked adrenoleukodystrophy (X‑ALD) have no approved pharmacologic therapy; disease management relies on high‑risk hematopoietic stem‑cell transplantation or supportive care, leading to rapid neurological decline and high unmet medical need.
Solution
Minoryx Therapeutics is advancing leriglitazone, an orally bioavailable, brain‑penetrant, selective PPAR‑γ agonist, to address the pathogenic cascade in X‑ALD and related orphan CNS diseases. The compound engages PPAR‑γ in the CNS at exposure levels unattainable with existing glitazones, restoring mitochondrial function, reducing oxidative stress, and modulating neuroinflammation. In the pivotal phase 2/3 ADVANCE trial (116 adult males), leriglitazone significantly slowed cerebral lesion progression and myelopathy symptoms. Open‑label NEXUS data in pediatric cALD patients demonstrated disease stabilization after 24 weeks. A phase 3 CALYX study is recruiting adult males with progressive cALD, and proof‑of‑concept programs are ongoing in Friedreich’s ataxia, Rett syndrome, and other neurodegenerative indications. The drug has received orphan‑drug, fast‑track, and rare‑pediatric‑disease designations in the EU and US, and a marketing‑authorization application is under EMA review.
Target Audience
Neurologists, metabolic disease specialists, and transplant centers managing X‑ALD and other orphan CNS disorders, as well as patients and families seeking disease‑modifying therapies for these rare conditions.
Features
- Highly selective PPAR‑γ agonist with >10‑fold brain exposure versus peripheral exposure, achieved through a proprietary oral suspension formulation.
- Demonstrated pharmacodynamic activity in preclinical models of X‑ALD, Friedreich’s ataxia, Rett syndrome, and other mitochondrial/oxidative‑stress–driven CNS disorders.
- Robust clinical data: phase 2/3 ADVANCE showed statistically significant reduction in cerebral lesion volume and myelopathy progression; NEXUS interim analysis confirmed radiologic disease arrest in pediatric cALD.
- Integrated physiologically‑based pharmacokinetic (PBPK) modeling supports dose optimization across adult and pediatric populations.
- Granted orphan‑drug designation (EU, US) and rare‑pediatric‑disease designation (US) for X‑ALD and FRDA, facilitating regulatory pathways.
- Scalable manufacturing process for a small‑molecule oral product, enabling global distribution upon approval.
- Compatibility with standard of care (e.g., hematopoietic stem‑cell transplantation) without requiring treatment interruption.